Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.
Saved in:
| Title: | Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. |
|---|---|
| Authors: | Reef DK; Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Grover N; Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. |
| Source: | AME clinical trials review [AME Clin Trials Rev] 2026 Apr 25; Vol. 4. Date of Electronic Publication: 2025 Dec 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: AME Publishing Company Country of Publication: China NLM ID: 9918994995006676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 3005-6152 (Electronic) Linking ISSN: 30056152 NLM ISO Abbreviation: AME Clin Trials Rev Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 3005-6152 |
|---|---|
| DOI: | 10.21037/actr-25-72 |
